WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
GMP Formulation, Fill and Lyophilization
GMP mAb Intermediate and Conjugation Manufacturing
WuXi Biologics Announces Proposed Spin-off and Separate Listing of WuXi XDC on the Hong Kong Stock Exchange
Hong Kong, China, July 9, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the proposed spin-off and separate listing of its subsidiary WuXi XDC Cayman...WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics
SHANGHAI, China, April 17, 2023 — WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) and its subsidiary WuXi XDC congratulate their partner DualityBio, a clinical-stage biotech company...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?